The 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium took place from February 13-15, 2025, at Moscone West in San Francisco, CA. This event provided attendees with expert, multidisciplinary insights into the latest clinical and scientific advancements in the field of genitourinary cancers. Additionally, the symposium offered a valuable opportunity for networking and collaboration with peers and industry thought leaders.
Below are concise summaries of studies presented at the 2025 ASCO GU Symposium that specifically highlight advancements in prostate cancer research.
- The potential of carbon ion radiation therapy (CIRT) as a curative treatment for localized prostate cancer (PCa) has attracted significant attention due to its unique dose distribution characteristics. However, there is currently a lack of data regarding the long-term effects on urinary function and changes in prostate volume in patients with PCa following CIRT treatment.
- To address this gap in knowledge, a prospective study was conducted spanning over five years to investigate the outcomes related to urinary function in patients with localized PCa who underwent CIRT treatment. The findings shed light on the changes in urinary function and prostate volume in these patients over the long term. The results of the study suggest that complications in patients undergoing CIRT treatment may be predictable through pre-treatment evaluations.
- There are numerous real-world data sources available for prostate cancer (PC), each with its own set of limitations. One of the most significant limitations is the lack of a complete understanding of the multidisciplinary clinical management of PC. The PRECISION data platform, which is the largest, most comprehensive, and continuously updated real-world evidence source on patients with advanced PC, aims to address this limitation and provide insights into PC management in both urology and oncology practices in academic and community settings in the United States.
- The platform contains a wide range of PC-specific data variables related to patients with metastatic hormone-sensitive PC (mHSPC) and metastatic castration-resistant PC (mCRPC) who have been treated across the US. The goal of this study is to offer an overview of the characteristics, treatment patterns, and clinical outcomes of patients with mHSPC and mCRPC included in PRECISION up to this point.
- This analysis offers valuable insights into the patients included in the PRECISION data platform. The dataset represents a balanced split between oncology and urology centers, with a 70/30 ratio, and between academic and community settings, with a 40/60 split. The clinical profile, treatment patterns, and outcomes observed provide the most comprehensive representation of current treatment practices in the US.
Evaluating the rates of surgical overtreatment of prostate cancer.
- The overdiagnosis and overtreatment of prostate cancer pose significant challenges to public health and hinder effective prostate cancer screening efforts. In 2012, the US Preventive Services Task Force (USPSTF) advised against routine PSA screening due to concerns about the overtreatment of low-risk prostate cancer and the associated negative health outcomes. Subsequently, in 2018, the USPSTF updated its recommendation to suggest that PSA screening should only be considered after a thorough discussion with the patient, highlighting the risks of overtreatment.
- This study aimed to assess the rates of surgical overtreatment of prostate cancer over the past two decades. They found that the rate of surgical overtreatment of low-risk prostate cancer has significantly decreased during this time period. There has been a notable decrease in the proportion of radical prostatectomies (RPs) performed for low-grade prostate cancer, with those that are performed more likely to exhibit higher-risk preoperative characteristics.
Evaluating the impact of a community-based prostate cancer screening program.
- Research shows that one in eight men in the United States will receive a prostate cancer diagnosis in their lifetime. Detecting this disease early through routine screening not only provides more treatment options but also increases the likelihood of survival. Unfortunately, barriers to screening exist, leading to disparities in prostate cancer rates, especially among Black males and individuals with limited access to healthcare.
- To address these disparities, community-based screening programs have emerged as a promising solution. By offering screenings in local neighborhoods and eliminating barriers related to cost and access, these programs can reach individuals who stand to benefit the most from early detection.
- In light of the concerning disparities in prostate cancer rates, particularly among Black males, it is crucial to implement interventions such as community-based screening events. These initiatives play a vital role in reducing barriers to screening, ultimately ensuring that those most in need receive the necessary care and support.
GLP-1 analogues and prostate cancer incidence: A systematic review and meta-analysis.
- Initial findings from preclinical and observational studies suggest that GLP-1 receptor agonists (GLP-1RAs) may have the potential to lower the risk of developing prostate cancer (PCa). Our objective was to investigate the impact of GLP-1RAs on the incidence of PCa.
- The data showed a lower number of new PCa cases among individuals receiving GLP-1RAs compared to the control group. However, this difference did not reach statistical significance. The trials were limited in duration and lacked a predefined focus on this specific outcome. Further investigation is necessary to determine the effectiveness of GLP-1RAs in combating established PCa.
- In conclusion, while there is promising evidence suggesting a potential benefit of GLP-1RAs in reducing PCa risk, more comprehensive research is required to confirm these findings.
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.
- Enzalutamide is a powerful inhibitor of the androgen receptor signal that is commonly used in the treatment of various stages of prostate cancer. However, the use of enzalutamide can be complex due to its high potential for drug-drug interactions, especially in the older population of prostate cancer patients who often have multiple comorbidities and are taking several medications. One class of drugs frequently co-administered with enzalutamide is anticoagulants.
- While low-molecular-weight heparin has been shown to be safe when combined with enzalutamide, the safety of combining enzalutamide with newer, more patient-friendly direct oral anticoagulants is still uncertain. The aim of this study was to investigate whether there is a potential drug-drug interaction between enzalutamide and edoxaban.
- The study found that the average exposure to edoxaban was similar whether it was taken with or without enzalutamide. However, due to a wider confidence interval than expected, bioequivalence could not be definitively established. Nevertheless, the increased variability is not believed to have any significant clinical implications, indicating that these drugs can be safely co-administered in clinical practice.
Utility of extended interval dosing of denosumab in patients with metastatic prostate cancer.
- Bone-modifying agents, such as zoledronic acid and denosumab, are frequently utilized in patients with metastatic solid tumors to decrease the occurrence of skeletal-related events (SREs). The FDA-approved dosing schedule for both agents is every 4 weeks, however, in clinical practice, less frequent administration (e.g. every 12 weeks) is often preferred for patient convenience. While the efficacy and safety of extended interval regimens for zoledronic acid are well-established, there is limited evidence supporting this practice for denosumab.
- The research indicates that extending the dosing interval of denosumab in patients with metastatic prostate cancer does not increase the risk of developing SREs and may provide added convenience for patients. This suggests that extended interval dosing of denosumab could be a viable option for patients with metastatic prostate cancer.
The 2025 ASCO GU is set to be an enriching and informative event. We recommend clicking here to explore the comprehensive list of topics and sessions that will be covered at this significant event. Don’t miss the opportunity to expand your expertise.
Sign up for alerts and stay informed on the latest published guidelines and stay tuned for our recap post the conference.
Copyright © 2025 Guideline Central, All Rights Reserved.